Please assess the completion status of the following clinical trial:

Trial Title: PleuraSeal Post Market Study (Europe)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Pre-Operative Inclusion Criteria:~* Subjects 18 years of age or older~* Scheduled for an elective pulmonary lobectomy and segmentectomy (limited resection in case of reduced functional operability) in one or more lobes via an open thoracotomy~* Subject or authorized representative has been informed of the nature of the study and has provided written informed consent, approved by the appropriate Ethics Committee of teh respective clinical site~Pre-Operative Exclusion Criteria:~* Documented history of bleeding disorders and/or severely altered renal or hepatic function~* Compromised immune system (e.g., HIV/acquired immunodeficiency syndrome, immunosuppressive therapy)~* Prior ipsilateral thoracotomy~* Subject with Tuberculosis~* Extensive adhesions from previous thoracic trauma or surgery~* Undergoing lung volume reduction surgery, wedge resection, pneumonectomy, sleeve resection or bronchoplasty, blebectomy, bullectomy, pleurodesis, lung transplant, or living lobe transplant donor~* Subject has active systemic or pulmonary infection~* Treated with chronic steroid therapy unless discontinued more than 6 weeks prior to surgery (standard acute perioperative steroids are permitted). For purposes of this protocol, chronic steroid therapy is defined as greater than 4 weeks~* Pregnant (documented by pregnancy test), breast-feeding, or that wish to become pregnant during the course of the study or not willing to use birth control (e.g. IUD; oral, transdermal or parenteral contraceptives; abstinence)~* Documented history of uncontrolled diabetes~* Subject has an estimated life expectancy of less than 6 months~* Currently enrolled in another investigational drug or device trial that has not completed the primary endpoint or that clinically interferes with this study~* Congestive heart failure, cor pulmonale, or other condition that, in the opinion of the investigator, may jeopardize the subject's well-being and/or negatively impact the interpretation of data collected during the clinical study~* Unable to comply with the study requirements or follow-up schedule~Intra-Operative Inclusion Criteria:~* At least one intra-operative air leak identified during lung submersion leak test after the initial closure is completed~* Hemostasis must be confirmed prior to randomization~Intra-Operative Exclusion Criteria:~* Procedure performed via VATS only~* Air leaks originating from bronchioles \>1 mm in diameter that cannot be primarily closed or a residual tidal volume loss of \>=30%~* Extensive intra-thoracic adhesions present~* Exploratory thoracotomy performed only~* Pneumonectomy, wedge resection, sleeve resection, pleurodesis, bronchoplasty, blebectomy or bullectomy performed~* Incidental finding of any other pre-operative exclusion criteria~* Use of buttressing materials or other non-autologous staple/suture line reinforcement or other surgical sealants when used for pulmonary sealing (i.e., use of hemostatic agents for hemostasis is permitted); however, the sealant should not be applied over intact hemostatic material and all hemostat should be removed prior to sealant application~* Investigator determines that participation in the study may jeopardize the safety or welfare of the subject

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PleuraSeal (Type: EXPERIMENTAL): PleuraSeal Lung Sealant System
- Standard of Care (Type: ACTIVE_COMPARATOR): Standard tissue closure techniques (control) - sutures or staples only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete